press release
Nov. 20, 2013, 8:00 a.m. EST
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
NEW YORK, November 20, 2013 /PRNewswire via COMTEX/ -- Editor Note: For more information about this release, please scroll to bottom
Today, Analysts' Corner announced new research reports highlighting Cell Therapeutics, Inc. /quotes/zigman/11692802/delayed/quotes/nls/ctic CTIC +2.12% , Akorn, Inc. /quotes/zigman/67758/delayed/quotes/nls/akrx AKRX +2.53% , Ligand Pharmaceuticals Incorporated /quotes/zigman/1626750/delayed/quotes/nls/lgnd LGND +1.91% , Intercept Pharmaceuticals, Inc. /quotes/zigman/12230574/delayed/quotes/nls/icpt ICPT +3.12% , and Ariad Pharmaceuticals Inc. /quotes/zigman/57221/delayed/quotes/nls/aria ARIA +1.53% . Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Research Report Cell Therapeutics, Inc. (Cell Therapeutics) along with Baxter International Inc. (Baxter) announced that the two have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib - a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia, and certain solid tumors. Cell Therapeutics stated that under the terms of the agreement, Baxter gains exclusive commercialization rights for all indications for pacritinib outside the U.S., and the Company will commercialize pacritinib in the U.S. together with Baxter. Commenting on the agreement, James A. Bianco, M.D. President and CEO of Cell Therapeutics stated, "We believe Baxter represents the ideal strategic partner to achieve the full potential of pacritinib. Our two companies share a dedication to oncology and a vision for bringing this unique oral JAK2/FLT3 inhibitor to patients with certain blood cancers and solid tumors. This collaboration will provide additional financial resources and commercial expertise to position us to pursue the development, commercialization and market potential of pacritinib."
AI
